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ABSTRACT
Background Despite being highly preventable and treatable 
if diagnosed early, colorectal cancer (CRC) remains the 
second leading cause of cancer- related death in Europe. 
Limited information is available from the patient perspective 
on the persisting unmet needs of the journey of the patient 
with CRC.
Objective To capture European metastatic CRC (mCRC) 
patients’ insights during the patient journey (prediagnosis; 
diagnosis; postdiagnosis) through a patient survey.
Methods In total, 883 patients from 15 European countries 
participated. Participants were divided into four groups from 
Hungary, Poland, Serbia and ‘other European countries’ (n=103, 
163, 170 and 447 patients, respectively).
Results General awareness of CRC and its symptoms 
prediagnosis varied among groups, with patients from Poland 
recording the lowest levels. Screening practices and attitudes 
also varied; while more patients from Serbia had been invited 
to CRC screening (~15%) compared with the other groups, the 
ones not invited claimed mostly (~20%) that would not have 
attended if they had been invited. Whereas most patients were 
diagnosed within a month after the first consultation/positive 
screening, the percentages varied substantially being lowest 
among patients in Poland (~30%) and Serbia (~25%). Although 
CRC- related information provision varied, with most informed 
patients from Hungary (~90%) and least from Serbia (~50%), 
all groups requested an easier- to- understand language by the 
healthcare team. Approximately 50% of patients from Eastern 
Europe had to wait longer than a month to receive treatment, 
in contrast to ~30% from other European countries. All groups 
emphasised the unmet need for support from psychologists 
and other patients.
Conclusions Our survey reveals the key aspects of the 
journey of the patient with mCRC and highlights the areas 
of similarities and differences between patients with mCRC 
from Eastern Europe versus those from other European 
countries as well as among patients from different Eastern 
European countries, calling for improvement particularly 
around awareness, screening, treatment availability, 
communication and support networks.
Key questions
What is already known about this subject?
 ► Previous surveys capturing the views of patients with 
metastatic colorectal cancer (mCRC) are limited, re-
vealing some aspects on the emotional, financial, 
health- related quality of life and treatment- specific 
burdens, such as fears about recurrence, postsurgi-
cal symptoms or managing a stoma.
What does this study add?
 ► This is the first study that captures comprehensively 
the journey of European patients with mCRC from 
prediagnosis to postdiagnosis, providing a perspec-
tive from three Eastern European countries with 
high CRC mortality rates and healthcare systems 
with several limitations as well as that from other 
European countries.
 ► The results can help to prioritise the overlooked 
needs of patients with mCRC.
How might this impact on clinical practice?
 ► The national healthcare systems should address the 
findings that point to specific delays in treatment 
initiation, especially in Eastern Europe, and the need 
for more exhaustive screening for CRC.
 ► Healthcare teams looking after patients with CRC 
should look into emotional support and communi-
cation gaps.
 ► Healthcare professionals (HCPs), patients and carers 
and patient organisations should work together to 
fill these gaps.
 ► Digestive Cancers Europe and national patient or-
ganisations working on CRC with support from the 
national governments must help strengthen the 
relationships between HCPs and patients and help 
overcome communication barriers by providing ad-
ditional emotional support and information material 
in a patient- friendly language.
 ► HCPs should flag to patients the supportive role that 
patient organisation can have in the patient journey.
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INTRODUCTION
Colorectal cancer (CRC) is a collective term for cancer 
that starts in the colon or the rectum. Colon and rectal 
cancers are often grouped together because they have 
many features in common.1
Approximately 500 000 people are newly diagnosed 
with CRC every year in Europe,2 where CRC is the second 
leading cause of cancer- related death after lung cancer in 
both men and women; approximately 243 000 people die 
from CRC in Europe each year. It is second to only breast 
cancer as the most common cancer type in women and 
the third most common cancer type in men, after lung 
and prostate cancers.3
However, CRC is one of the most preventable cancers. 
Most CRCs develop from non- cancerous polyps—growths 
on the lining of the colon and rectum—and screening 
methods can detect and remove polyps before they 
become cancerous.4 If it is detected early, the chance of 
cure is very high. The 5- year survival rate of people with 
localised- stage CRC is 90%. However, if the cancer has 
spread (metastasised) to distant parts of the body, the 
5- year survival rate is only 14%.5
Despite this knowledge and the fact that many EU 
Member States are running or establishing population- 
based CRC screening programmes,6 there is still signifi-
cant variability across Europe in terms of screening and 
outcome rates.7 Among CRC survivors, emotional, finan-
cial, health- related quality of life (QoL) and treatment- 
specific burdens, such as fears about recurrence, 
postsurgical symptoms or managing a stoma, have all 
been documented.8–11 However, there is limited informa-
tion on the patient experience among patients with meta-
static CRC (mCRC).
In 2016, Digestive Cancers Europe (DiCE) - Europa-
Colon at the time - a European patient organisation that 
aims to give a voice to people living with all types of diges-
tive cancers, initiated a multinational survey to under-
stand the mCRC patient journey before, during and after 
diagnosis. The survey consisted of two parts. The purpose 
of the first part of the survey was to facilitate a better 
understanding on screening practices, disease awareness, 
sources and quality of available information on mCRC 
and treatments, communication with healthcare profes-
sionals (HCPs) and the level of participation in treatment 
decisions and the sources and quality of support provided 
in patients with mCRC from Eastern Europe and other 
European countries.
The second part of the survey focused on the QoL of 
patients with mCRC after diagnosis. The results from the 
second part of the survey will be published separately.
METHODS
The first part of the survey was developed by DiCE 
(formerly EuropaColon) and their Expert Patient Advi-
sory Group. It was reviewed by Evidera, who are experts 
in outcome research. The questionnaire comprised of 
four sections, each of which contained a comprehensive 
question set. When analysing the data, we limited our 
analysis to questions we considered most relevant and 
important (final) and did not include all (initial). The 
number of initial and final questions and the different 
parts of the survey were as follows: part 1 consisted of 
questions related to the patient profile (initial, 12; final, 
7); part 2 contained questions about the patient journey 
and was divided into the following four topics related 
to the prediagnostic, diagnostic and postdiagnostic 
stages of the disease: (1) discovery of illness (initial, 16; 
final, 9), (2) diagnosis (initial, 4; final, 4), (3) treatment 
(initial, 21; final, 18) and (4) patient support (initial, 12; 
final, 11). Online supplemental appendix 1 includes all 
analysed survey questions (final); parts 3 and 4 - QLQ- C30 
and QLQ- CR29, respectively - captured the patients’ QoL; 
these results will be presented separately (in preparation). 
Patients with mCRC, independently of whether they were 
newly diagnosed or not, were eligible to participate in 
the survey. The method for patient recruitment varied 
by country, depending on the local legal framework as 
well as the national patient organisation supporting the 
survey. All participants were informed why the study was 
being done as well as how the results of the survey would 
be used prior to completing it. Patients were invited to 
participate via direct outreach with a leaflet by national 
patient organisations or clinicians or via an invitation 
on the EuropaColon website or social media announce-
ments (mainly via Twitter). Because of these two different 
recruitment approaches, we were not able to capture 
the response rate of the survey. Patients had the option 
to either complete the survey online via a secure link 
or a paper version given to them by members of their 
healthcare team. Taking part in the survey implied that 
participants consented to it. Institutional Review Board 
approvals were obtained where needed. The survey 
responses were anonymised, and no patient organisations 
or clinicians received monetary compensation to promote 
and/or conduct the survey. The survey was accessible for 
18 months (June 2017−December 2018) and translated 
into 10 languages. We aimed to capture the views of at 
least 100 patients in each of the three participant Eastern 
European countries, independently of the country’s popu-
lation size or the incidence of CRC, and we also targeted 
patients from all over Europe, especially in regions where 
we had strong relationships with national patient organi-
sations and/or clinicians. The national participating sites 
were recruited by the national patient organisations and 
included mainly tertiary referral centres.
RESULTS
Patient demographics
A total of 883 people across 15 countries in Europe, who 
had received a diagnosis of mCRC, completed the survey. 
Patients were divided into four groups as follows: group 
1, 103 patients (35.92%, men; 51.46%, women) from 
Hungary (mean age, 62.06 years); group 2, 163 patients 
(57.67%, men; 39.26%, women) from Poland (mean age, 
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63.65 years); group 3, 170 patients (58.24%, men; 41.76%, 
women) from Serbia (mean age, 65.33 years) and group 
4, 447 patients (39.15%, men; 41.39, women) from ‘other 
European countries’ (mean age, 50.67) (see online 
supplemental appendix 2 for participant breakdown by 
country). Patient demographic data are presented in 
detail in table 1.
The patient journey—prediagnosis
CRC awareness
Patients were asked a series of questions to capture their 
awareness on CRC- related symptoms. Most respondents 
from Hungary (40.78%) and Serbia (47.06%) consulted 
their physician because of CRC- related symptoms, and 
these percentages were slightly higher to those of patients 
from other European countries (38.93%). In Poland, the 
number of patients who consulted their physician because 
of CRC- related symptoms (33.13%) was lower than that 
in other countries. In addition, the number of responses 
from Poland (10.43%) regarding CRC symptom aware-
ness before diagnosis was lower to that from Hungary 
(29.13%) and the other European countries (28.64%), 
while those from Serbia were the highest (37.65%).
When asked if they were well informed or knew some-
thing about CRC before diagnosis (not limited to symp-
toms), the most positive responses were from Hungary 
(40.78%) and Serbia (38.82%), with less from other 
European countries (30.20%) and the least from Poland 
(14.72%).
Screening
Regarding screening, only 1.94% of participants from 
Hungary and 3.07% from Poland had been invited to 
participate in a CRC screening programme and had 












Sex Male 37 (35.92) 94 (57.67) 99 (58.24) 175 (39.15)
N* (%) Female 53 (51.46) 64 (39.26) 71 (41.76) 185 (41.39)
Age (years) ≥71 22 (21.36) 38 (23.31) 45 (26.47) 81 (18.12)
N* (%) 61–70 47 (45.63) 71 (43.56) 76 (44.71) 173 (38.70)
  51–60 17 (16.50) 35 (21.47) 36 (21.18) 116 (25.95)
  ≤50 16 (15.53) 2 (1.23) 2 (1.18) 65 (14.54)
Marital status Single 7 (6.8) 4 (2.45) 1 (0.59) 29 (6.49)
N* (%) Married/partner 71 (68.93) 124 (76.07) 128 (75.29) 364 (81.43)
  Divorced 13 (12.62) 11 (6.75) 9 (5.29) 27 (6.04)
  Widowed 12 (11.65) 24 (14.72) 32 (18.82) 23 (5.15)
Areas of living Rural 8 (7.77) 51 (31.29) 42 (24.71) 67 (14.99)
  Semiurban 28 (27.18) 50 (30.67) 45 (26.47) 148 (33.11)
  Urban 16 (15.53) 46 (28.22) 35 (20.59) 135 (30.20)
  Capital city 50 (48.54) 16 (9.82) 48 (28.24) 92 (20.58)
Education None 1 (0.97) 0 1 (0.59) 4 (0.89)
  Primary 15 (14.56) 29 (17.79) 22 (12.94) 104 (23.27)
  Secondary 47 (45.63) 92 (56.44) 106 (62.35) 119 (26.62)
  College 19 (18.45) 6 (3.68) 24 (14.12) 100 (22.37)
  University 18 (17.48) 21 (12.88) 11 (6.47) 102 (22.82)
  Postgraduate 3 (2.91) 8 (4.91) 1 (0.59) 45 (10.07)
  I do not know 0 3 (1.84) 0 3 (0.67)
Employment Employed 16 (15.53) 25 (15.34) 24 (14.12) 120 (26.85)
Status N* (%) Unemployed 2 (1.94) 3 (1.84) 12 (7.06) 17 (3.80)
  Retired 65 (63.11) 100 (61.35) 124 (72.94) 213 (47.65)
  Unemployed due to a medical 
condition
6 (5.83) 20 (12.27) 1 (0.59) 52 (11.63)
  Student/intern 0 0 0 2 (0.45)
  Other 10 (9.71) 14 (8.59) 5 (2.94) 26 (5.82)
*Missing values throughout the table correspond to number of non- respondents.
†Respondents in Cyprus were not asked their age for reasons of anonymity.
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attended, while 3.88% from Hungary and 1.23% from 
Poland had received an invitation for screening but 
declined to attend. In contrast, a higher number of partic-
ipants from Serbia who had been invited to participate 
had attended (15.88%), while 9.41% had been invited 
but declined; these responses were slightly higher than 
those obtained for patients from other European coun-
tries (13.20% were invited and attended and 7.38% were 
invited but declined). It should be added that 15.53% of 
patients from Hungary, 4.91% from Poland, 7.06% from 
Serbia and 18.12% from other European countries were 
younger than 50 years old and, hence, not eligible to 
participate in a screening programme.
Furthermore, 54.37% of patients from Hungary, 
60.74% from Poland, 40% from Serbia and 35.35% from 
other European countries said they were not invited for 
screening but were both eligible (≥50 years) and would 
have attended if asked, while 17.48% from Hungary, 
9.82% from Poland, 20.59% from Serbia and 8.95% 
from other European countries said that while they were 
eligible (≥50 years), they would not have attended anyway.
The patient journey—diagnosis
Patients were then asked to evaluate some aspects around 
their diagnosis, including how long their diagnosis took 
from the moment of the first consultation or positive 
screening test and how accurate their first diagnosis was. 
Most patients from Hungary were diagnosed within 2 
weeks, similar to patients from other European countries 
(Hungary, 55.34%; other European countries, 57.05%), 
while 80.58% and 76.74% of these patients, respec-
tively, were diagnosed within the first month. A similar 
trend but at a lower rate was observed among patients in 
Poland, with 31.90% diagnosed within the first 2 weeks 
and 57.05% within the first month. Patients from Serbia 
reported the longest delays in diagnosis, with only 24.12% 
diagnosed within 2 weeks and 48.24% diagnosed within a 
month. Although the levels of misdiagnosis were highest 
among patients in Serbia (27.65%) compared with those 
in Hungary (16.5%) and Poland (18.4%), they were close 
to those reported by patients in other European countries 
(25.95%).
The patient journey—after diagnosis
HCP-patient communication
When asked to evaluate the levels of information they had 
received by their HCP, patients from Hungary showed the 
highest levels of satisfaction among all patient groups, 
with 91.26% agreeing or strongly agreeing they had been 
given enough information compared with 62.57% of 
patients from Poland, 49.42% from Serbia and 67.56% 
from other European countries.
Patients were asked if they had received clear infor-
mation from their doctor on a range of topics related 
to their diagnosis including disease nature, origin, 
stages and progression, examinations, possible treat-
ments, consequences and side effects (figure 1, top 
graph). Although the percentages differed in different 
countries, the trend was similar among groups with 
information on examinations, the nature of disease, 
possible treatments and consequence of treatments 
and side effects receiving the most positive responses 
(figure 1, top graph). In agreement with the levels of 
satisfaction regarding the information they received, 
patients from Hungary were the best informed among 
all groups (figure 1, top graph).
Respondents indicated that the information most 
important to them was that about the disease, treatments, 
side effects and clinical trials and this was consistent 
among all four patient groups (figure 1, bottom graph).
Treatment
Although most patients from all four groups were under-
going treatment at the time of the survey, the percent-
ages varied (Hungary, 91.26%; Poland, 90.18%; Serbia, 
55.29%; other European countries, 61.74%). The 
percentage of patients who had to wait for more than a 
month after diagnosis to receive treatment was similar 
among patients in Hungary (47.57%), Poland (49.08%) 
and Serbia (49.41) but higher than that of patients from 
other European countries (29.30%). The percentage of 
patients who had to wait for more than a year after diag-
nosis to receive treatment was 3.88% in Hungary, 5.52% 
in Poland and 4.71% in Serbia, while in other European 
countries, it was only 0.45%.
Most respondents from all four groups received surgery 
and chemotherapy; very few respondents from Hungary, 
Poland and Serbia received other treatments, such as 
immunotherapy, or entered a clinical trial, in contrast to 
7.16% of patients from other European countries. The 
breakdown for all treatments is shown in figure 2 (top 
graph).
A great variation was observed among countries in the 
number of patients who felt that their views were consid-
ered when it came to treatment decisions, with the most 
positive answers from patients in Hungary (82.52%) 
and the least in Serbia (29.41%), while the number of 
positive responses from patients in Poland (51.53%) was 
similar to that of patients from other European countries 
(56.15%). The number of patients who did not know 
what type of chemotherapy drugs they had received 
varied from approximately 25% to 35% (Hungary, 23.3%; 
Poland, 28.83%; Serbia, 36.47%; other European coun-
tries, 26.85%).
When asked whether they underwent molecular 
testing for RAS, patients from Poland showed the highest 
percentage of affirmative responses (31.9%) compared 
with those of the other groups, while a high percentage of 
patients from Serbia (38.24%) did not know what molec-
ular testing was (figure 2, bottom graph).
Levels of support
Patients stated that their partners and their children were 
their main source of support followed by their friends, 
and this was consistent across groups (figure 3, top left 
graph).
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Most patients were largely satisfied with the level of 
emotional support they received from clinicians and 
nurses, except for patients in Serbia who showed consider-
ably lower levels of satisfaction (figure 3, top right graph). 
When asked what would improve the relationship with the 
healthcare team the most overall popular response was 
‘to be spoken to in a language I can understand’, which 
was opted by 56% of patients from Serbia. Although the 
percentages of the different responses varied among 
groups, other popular responses included inclusion in 
Figure 1 Colorectal cancer (CRC) information provision at and after diagnosis for patients with metastatic CRC from 
Hungary, Poland, Serbia and other European countries. The top graph depicts the percentage of respondents who received 
clear information on different disease topics at diagnosis, while the bottom graph shows the topics that are most important for 
patients from each of the four groups.
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shared decision- making and being treated as an indi-
vidual and not as a number (figure 3, middle graph).
Patients were asked what would help that is not 
currently available to them; the top two answers selected 
among patients from Eastern Europe were a psycholo-
gist and talking to other patients, while those from other 
European countries mostly preferred apps for mobiles 
and/or tablets and a psychologist. For patients from 
Eastern Europe, the next preferred option included 
patient support programmes or apps, while from other 
European countries, a helpline was among the first three 
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Figure 2 Types of treatment and molecular testing for patients with metastatic colorectal cancer from Hungary, Poland, 
Serbia and other European countries. The top graph depicts the different treatments that patients received, while the bottom 
graph shows the percentage of respondents who received molecular testing and their awareness around it.
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Figure 3 Understanding the support provision and areas of improvement in the patient- healthcare professional (HCP) 
relationship in patients with metastatic colorectal cancer (mCRC) from Hungary, Poland, Serbia and other European countries.
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Impact on life
A very high number of respondents from Serbia (78.24%) 
said they had encountered difficulties (physical, financial 
or other) as a result of their CRC diagnosis, while 24.27% 
from Hungary, 48.47% from Poland and 37.36% from 
other European countries gave an affirmative response 
to this question. More patients from other European 
countries (7.61%) and Hungary (6.8%) lost their jobs 
compared with those from Poland (4.91%) and Serbia 
(2.35%). However, patients from Hungary seemed to 
be less affected financially because of their diagnosis 
compared with patients from the other groups (figure 4).
DISCUSSION
CRC is differentiated from many other types of cancer in 
that it is ‘preventable, treatable and beatable’.12 However, 
it is still the second leading cause of cancer- related death 
in both men and women in Europe.3 Therefore, it is 
instructive to look at the patient journey before, during 
and after diagnosis, to understand patients’ challenges 
and barriers, which could be overcome to help improve 
outcomes.
The survey has highlighted some areas with consider-
able similarities and differences between patients with 
CRC from Eastern Europe versus those from other Euro-
pean countries as well as among patients from three 
Eastern European countries (Hungary, Poland and 
Serbia). These three countries not only share geograph-
ical similarities but also show high CRC mortality levels13 
and limitations in their healthcare systems compared with 
other countries in Europe.14
Our survey revealed lowest CRC symptom awareness 
among patients from Poland and highest among patients 
from Serbia compared with the other groups. Moreover, 
patients from Poland were also the least knowledgeable 
about CRC among the four groups of patients.
Although our survey included a variable number of 
patients (~5–18%) younger than 50 years old who would 
not have been invited to CRC screening, the number of 
eligible patients who had overall participated was very low 
in Hungary (1.94%) and Poland (3.07%) and relatively 
higher in Serbia (15.88%) and other European coun-
tries (13.20%). In 2015, 24 countries in the European 
Union had established or were preparing to organise 
country- wide CRC screening programmes for people 50 
years or older.15 An analysis of different programmes in 
several European countries showed that the lowest partic-
ipation rates in Europe (eg, in Croatia and the Czech 
Republic) were under 25%,6 but not as low as suggested 
by our survey. However, the All.Can survey16 revealed that 
only 14% of patients with CRC said their diagnosis came 
about as part of a routine screening programme, which is 
similar to the result of our survey (13.2% of patients from 
other European countries).
Our survey also revealed a significant minority of 
patients who fall into the defined average- risk popu-
lation for CRC screening (individuals ≥50 years, with 
no additional risk factors), but either were invited but 
declined the invitation to a screening programme (7% of 
patients from other European countries) or who would 
decline such an invitation if they received one (9% of 
patients from other European countries). These results 
Figure 4 Financial hardship of patients with metastatic colorectal cancer from Hungary, Poland, Serbia and other European 
countries. Graph showing the percentage of the different problems patients from each of the four groups face.
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suggest a need for better awareness around CRC and 
CRC screening, which is supported by the relatively low 
percentage of patients (30% of patients from other Euro-
pean countries) who knew something about CRC prior to 
their diagnosis. However, although patients from Serbia 
were better informed about CRC before diagnosis (40% 
of patients) compared with the other patient groups, they 
would decline at a higher rate (~20%) a screening invita-
tion if they received one. This indicates that other factors, 
such as cultural beliefs, misconceptions and different 
attitudes around CRC screening, may also contribute to 
low participation in screening programmes and empha-
sises the need to consider this when trying to improve 
screening patient uptake.
Our survey revealed differences in the time of diagnosis 
between patient groups; approximately 80% of respon-
dents from Hungary and other European countries were 
diagnosed within the first month after the first consul-
tation or positive screening test, while ~60% of patients 
from Poland and ~50% from Serbia were diagnosed 
within this time frame. An additional concern to the 
delays in diagnosis in patients from Serbia is the fact that 
approximately one- third of these patients were initially 
misdiagnosed, while in other European countries, the 
misdiagnosis rate was one in four. This corresponds to the 
findings from the All.Can survey, where 21% of respon-
dents with CRC said their cancer was initially diagnosed 
as something different.16
It is reassuring that the majority of patients agreed or 
strongly agreed that they were given enough information 
by their HCPs. However, the percentages of informed 
patients varied among patient groups, with patients from 
Hungary (~90%) being the most informed and those 
from Serbia (~50%) the least. Well- informed patients 
from other European countries were ~68%, similar to 
the result produced by the All.Can survey, with 62% of 
patients saying they were given enough information 
about their cancer care and treatment.16
Patients from the four groups were generally satis-
fied with the level of information they received around 
the nature of the disease, examinations and treatments 
and consequences and side effects; however, substantial 
knowledge gaps remained around the origin, stages and 
progression of the disease, with approximately half or 
less than half of patients having received information on 
these topics. Previous studies have shown that patients 
with fulfilled information needs, and patients who expe-
rience less information barriers, in general have a better 
QoL and less anxiety and depression17 ; hence, adequate 
information provision is a very important need to address 
in the CRC patient journey. However, this information 
needs to be delivered in a clear, non- technical format, as 
highlighted by patients from all four groups.
Approximately 30% of patients from other European 
countries had to wait for more than a month to receive treat-
ment, while in each of the three Eastern European coun-
tries, this reached ~50% of patients. Moreover, the number 
of patients from Eastern Europe who had to wait for more 
than a year to receive treatment was considerably higher 
(3.9–5.5%) to that in other European countries (0.45%), 
raising concerns about the availability of hospitals, consul-
tants and treatments in Eastern Europe, in accordance with 
the previous reports.14 Prompt CRC treatment is crucial 
as studies have shown that survival is improved in patients 
treated within 30 days of their diagnosis.18
The latest treatment guidelines from the European 
Society for Medical Oncology state that biological (person-
alised) medicines are indicated for the treatment of 
patients with mCRC19 ; however, substantial variations in 
the number of patients who received personalised medi-
cines was observed among the country groups, with the 
highest rates observed in Hungary (22%) and the lowest 
in Serbia (0.59%). This may be, at least in part, a conse-
quence of the fact that at the time of the survey, person-
alised treatment for mCRC was not reimbursed in Poland 
and was reimbursed with restrictions in Serbia. The 
number of patients from Eastern Europe who received 
immunotherapy or participated in a clinical trial neared 
zero, while that of patients from other European coun-
tries was ~7%. Molecular testing practices also varied 
among patient groups, with ~50% or more of patients 
not knowing whether they had been tested or what RAS 
testing was.
The survey also revealed that when it comes to treat-
ment decisions, most of patients’ views are not consid-
ered, although the high percentage of positive answers 
by patients from Hungary was a promising exception. 
Patients in Serbia felt the least included in treatment 
decisions, in line with the fact they were the least aware of 
the type of chemotherapy drugs they received.
The survey confirms the vital role that family members 
have in supporting CRC patients, particularly partners 
and children, which was consistent throughout the four 
groups. It is estimated that family caregivers provide over 
half of the care needed by cancer patients20 and that 
cancer patients want medical decisions to be made in 
conjunction with family members.21 22 More than half of 
all patients were very satisfied with the emotional support 
they received from their clinicians and nurses, except for 
patients from Serbia who showed lower rates of satisfac-
tion (~35%). In fact, patients from Serbia opted overall 
for more issues than need to be tackled to improve the 
relationship with the healthcare team compared with 
patients from the other three groups.
Approximately a quarter of patients from Eastern 
Europe said they would benefit from seeing a psycholo-
gist, with a slightly lower percentage among patients from 
other European countries. A previous report suggests 
that a significant minority of CRC survivors experience 
clinically meaningful distress across the trajectory of the 
illness,23 validating the need for professional support 
for some patients. The number of patients who agreed 
that talking to other patients and having patient support 
programmes in place would help (but are not currently 
available) shows the importance of building communi-
ties of patients. In addition, the request for specific apps 
Open access
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highlights the importance that technology can play in 
supporting patients.
It is not surprising that at least one in five of the respon-
dents from the four groups had encountered difficulties 
during their patient journey. However, it is concerning 
that this was the case among ~50% and ~80% of patients 
in Poland and Serbia, respectively, in agreement with the 
highest number of patients from these countries having 
their income negatively affected as a result of their diagnosis.
Although we cannot be absolutely certain about the gener-
alisability of the data presented, several facts are in favour of 
it. As mentioned above, some of the results captured were 
in accordance with those obtained in the All.Can survey.16 
In addition, the answers of patients from Eastern Europe, 
and especially those from Serbia and Poland, revealed the 
biggest gaps in information provision, treatment availability 
and support, which coincides with the fact that these coun-
tries have more limited healthcare resources compared 
with those of other European countries.14
Even though this survey represents the first attempt to 
capture different stages of the mCRC patient journey, it has 
some limitations. One can argue that the patient sample 
(883 patients overall; 447 patients from other European 
countries) is not large enough to draw strong conclusions. 
However, the All.Can International Cancer Patient Survey 
aiming at obtaining the patient perspective in insufficien-
cies in cancer care is considered the biggest survey of its kind 
with 3981 respondents from more than 10 countries world-
wide,16 reflecting that recruiting large number of cancer 
patients is challenging. Other limitations include that the 
number of screening participants might be underestimated 
due to a selection bias since the survey was addressed to 
patients at the metastatic stage rather than to all patients 
with CRC.
CONCLUSION
Faced with CRC being the second leading cause of cancer- 
related death in Europe, it is essential to look at the patient 
journey from all perspectives. The survey revealed several 
key areas in CRC that require attention and improve-
ment, including awareness of CRC and its symptoms, low 
rates of CRC screening and a reluctance to participate 
even if available, lack of provision of information and the 
need for greater patient support including psychologists, 
patient networks and patient support programmes.
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